Capstan Therapeutics
Targeted lipid nanoparticles for in vivo CAR-T cell reprogramming
- Sector
- Biotech
- Founded
- 2020
- Latest Form D
- $87.5M, Mar 2024
- Total capital
- $227M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $227M
- 3 Form D · last Mar 2024
- 31 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 16 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$87.5M
- Private capital raisedForm D · SEC · 2nd filing$76.5M
- Private capital raisedForm D · SEC · 1st filing$63M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Adrian BotExecutive OfficerNamed in SEC Form D filings
- Athena CountouriotisDirectorNamed in SEC Form D filings
- Erez ChimovitsDirectorNamed in SEC Form D filings
- Fabio PucciDirectorNamed in SEC Form D filings
- Justin ThackerExecutive OfficerNamed in SEC Form D filings
- Karen SmithDirectorNamed in SEC Form D filings
Show all 14 people
- Laura ShawverExecutive Officer, DirectorNamed in SEC Form D filings
- Michael BaranDirectorNamed in SEC Form D filings
- Michal SilverbergDirectorNamed in SEC Form D filings
- Nandita ShangariDirectorNamed in SEC Form D filings
- Nanna LuneborgDirectorNamed in SEC Form D filings
- Priya KarmaliExecutive OfficerNamed in SEC Form D filings
- Rajul JainDirectorNamed in SEC Form D filings
- Ramin Farzaneh-FarExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 16- PendingPeg-lipids And Lipid NanoparticlesUSPTOApplication 18853665
- PendingRNA for In vivo Transfection with Increased ExpressionUSPTOApplication 18934237
- PendingConstrained Ionizable Cationic Lipids and Lipid NanoparticlesUSPTOApplication 18904951
Show all 16 patent records
- Peg-lipids And Lipid NanoparticlesJul 24, 2025 · Application 18853665Pending
- RNA for In vivo Transfection with Increased ExpressionMay 8, 2025 · Application 18934237Pending
- Constrained Ionizable Cationic Lipids and Lipid NanoparticlesApr 24, 2025 · Application 18904951Pending
- RNA for In vivo Transfection with Increased ExpressionApplication 63708529Pending
- Ionizable Cationic Lipids With Conserved Spacing And Lipid NanoparticlesApplication PCTUS2024049627Pending
- Constrained Ionizable Cationic Lipids And Lipid NanoparticlesApplication PCTUS2024049649Pending
- Extracorporeal And Ex Vivo Engineering Of Select Cell Populations From Peripheral BloodApplication PCTUS2024035902Pending
- Constrained Ionizable Cationic Lipids And Lipid NanoparticlesApplication 63654744Pending
- Constrained Ionizable Cationic Lipids And Lipid NanoparticlesApplication 63654720Pending
- Lipid Nanoparticle Formulations And CompositionsApplication PCTUS2024032141Pending
- Ionizable Cationic Lipids And Lipid NanoparticlesApplication 63654704Pending
- Ionizable Cationic Lipids With Conserved Spacing And Lipid NanoparticlesApplication 63654752Pending
- Immune Engineering AmplificationApplication 63721154Pending
- RNA for In vivo Transfection with Increased ExpressionApplication 63654928Pending
- Rna For In Vivo Transfection With Increased ExpressionApplication PCTUS2024054033Pending
- Humanized ANTI-CD8 Antibodies And Uses ThereofApplication 63708461Pending
Related companies, and why
- EvommuneSimilar federal contract value in Biotech · null in contracts
- eGenesisSimilar federal contract value in Biotech · null in contracts
- Verona Pharma plcSimilar federal contract value in Biotech · null in contracts
- Apnimed, Inc.Similar federal contract value in Biotech · null in contracts
- Seaport TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Rivus PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .